Intersect ENT, Inc. (NASDAQ:XENT) – Research analysts at Leerink Swann issued their Q2 2018 earnings per share estimates for shares of Intersect ENT in a report issued on Monday. Leerink Swann analyst R. Newitter forecasts that the medical equipment provider will earn ($0.11) per share for the quarter. Leerink Swann also issued estimates for Intersect ENT’s Q3 2018 earnings at ($0.11) EPS and FY2020 earnings at $0.43 EPS.
XENT has been the subject of several other reports. Northland Securities reissued a “hold” rating and set a $25.00 target price on shares of Intersect ENT in a research note on Wednesday, August 2nd. Zacks Investment Research cut Intersect ENT from a “hold” rating to a “sell” rating in a research note on Wednesday, July 5th. BidaskClub cut Intersect ENT from a “buy” rating to a “hold” rating in a research note on Wednesday, August 2nd. TheStreet raised Intersect ENT from a “d” rating to a “c-” rating in a research note on Tuesday, August 1st. Finally, Deutsche Bank AG set a $31.00 target price on Intersect ENT and gave the stock a “buy” rating in a research note on Wednesday, August 2nd. Four research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Intersect ENT has an average rating of “Buy” and a consensus price target of $27.70.
COPYRIGHT VIOLATION NOTICE: This report was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://www.dispatchtribunal.com/2017/10/27/research-analysts-issue-forecasts-for-intersect-ent-inc-s-q2-2018-earnings-xent.html.
Shares of Intersect ENT (NASDAQ:XENT) traded up 1.57% during midday trading on Tuesday, hitting $29.10. The company had a trading volume of 26,999 shares. The company has a 50-day moving average of $30.18 and a 200 day moving average of $26.24. The firm’s market capitalization is $849.40 million. Intersect ENT has a 12 month low of $7.65 and a 12 month high of $33.25.
Intersect ENT (NASDAQ:XENT) last issued its quarterly earnings data on Tuesday, August 1st. The medical equipment provider reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.11. The firm had revenue of $24.00 million during the quarter, compared to analysts’ expectations of $22.62 million. Intersect ENT had a negative return on equity of 17.60% and a negative net margin of 22.94%. The firm’s quarterly revenue was up 24.4% on a year-over-year basis. During the same period in the prior year, the business posted ($0.21) EPS.
In other Intersect ENT news, CFO Jeryl L. Hilleman sold 12,833 shares of Intersect ENT stock in a transaction dated Friday, August 4th. The stock was sold at an average price of $29.00, for a total transaction of $372,157.00. Following the completion of the sale, the chief financial officer now directly owns 27,833 shares of the company’s stock, valued at approximately $807,157. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Lisa D. Earnhardt sold 20,000 shares of Intersect ENT stock in a transaction dated Monday, October 16th. The stock was sold at an average price of $28.37, for a total value of $567,400.00. The disclosure for this sale can be found here. Insiders have sold a total of 147,063 shares of company stock valued at $4,368,029 over the last ninety days. 13.70% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in XENT. Legal & General Group Plc lifted its holdings in Intersect ENT by 3.8% during the 2nd quarter. Legal & General Group Plc now owns 6,939 shares of the medical equipment provider’s stock worth $193,000 after buying an additional 255 shares during the last quarter. Cornerstone Capital Management Holdings LLC. lifted its holdings in shares of Intersect ENT by 109.1% in the 1st quarter. Cornerstone Capital Management Holdings LLC. now owns 11,500 shares of the medical equipment provider’s stock valued at $196,000 after purchasing an additional 6,000 shares during the last quarter. Moors & Cabot Inc. purchased a new stake in shares of Intersect ENT in the 2nd quarter valued at about $205,000. Prudential Financial Inc. purchased a new stake in shares of Intersect ENT in the 2nd quarter valued at about $229,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of Intersect ENT in the 2nd quarter valued at about $229,000. 83.12% of the stock is owned by institutional investors.
About Intersect ENT
Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.
Receive News & Ratings for Intersect ENT Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT Inc. and related companies with MarketBeat.com's FREE daily email newsletter.